Physician profile
Christopher Fatone
NPI 1629035472
$1,540.90
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $130 · 2021: $183 · 2022: $605 · 2023: $278 · 2024: $53.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.35 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $200.94 | 2020-2022 | |
| Abbott Laboratories | $178.86 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $152.16 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $103.67 | 2019-2021 | |
| Amgen INC. | $91.52 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $58.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.33 | 2019 | |
| Pfizer INC. | $55.00 | 2021-2023 | |
| Ibsa Pharma INC. | $52.41 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.25 | 2019 | |
| Lilly USA, LLC | $46.47 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $39.06 | 2021-2022 | |
| Csl Behring | $37.50 | 2023 | Kcentra |
| Currax Pharmaceuticals LLC | $31.75 | 2022-2023 | Contrave, Onzetra Xsail |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.01 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.77 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.34 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.59 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.38 | 2021 | |
| Genentech USA, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fatone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.